Join Growin Stock Community!

Rapt therapeutics, inc.RAPT.US Overview

US StockHealthcare
(No presentation for RAPT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

RAPT AI Insights

RAPT Overall Performance

RAPT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RAPT Recent Performance

0.03%

Rapt therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

RAPT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

RAPT Key Information

RAPT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

RAPT Profile

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Price of RAPT

RAPT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.39
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
411.22
PB Ratio
11.05
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.39
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
411.22
PB Ratio
11.05
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is RAPT's latest earnings report released?

    The most recent financial report for Rapt therapeutics, inc. (RAPT) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RAPT's short-term business performance and financial health. For the latest updates on RAPT's earnings releases, visit this page regularly.

  • How much debt does RAPT have?

    As of the end of the reporting period, Rapt therapeutics, inc. (RAPT) had total debt of 2.6M, with a debt ratio of 0.02. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does RAPT have?

    At the end of the period, Rapt therapeutics, inc. (RAPT) held Total Cash and Cash Equivalents of 37.93M, accounting for 0.23 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is RAPT's EPS continuing to grow?

    According to the past four quarterly reports, Rapt therapeutics, inc. (RAPT)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.65. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of RAPT?

    Rapt therapeutics, inc. (RAPT)'s Free Cash Flow (FCF) for the period is -12.46M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 29.37% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

RAPT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1